|
Contemporary utilization trends and survival outcomes in patients undergoing radical cystectomy and bladder preservation therapy for muscle invasive bladder cancer. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Visible Health |
Leadership - Visible Health |
Stock and Other Ownership Interests - Visible Health |
Honoraria - Genomic Health |
Consulting or Advisory Role - Genomic Health |
Speakers' Bureau - Genomic Health |
Travel, Accommodations, Expenses - Genomic Health |
|
|
Honoraria - GlaxoSmithKline; Johnson & Johnson |
Consulting or Advisory Role - Myriad Genetics |
Speakers' Bureau - Janssen Oncology |
|
|
No Relationships to Disclose |